Articles

2012

1. Agnihotri S, Gajadhar AS, Ternamian C, Gorlia T, Diefes KL, Mischel PS, Kelly J, McGown G, Thorncroft M, Carlson BL, Sarkaria JN, Margison GP, Aldape K, Hawkins C, Hegi M, Guha A. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. J Clin Invest. 2012 Jan 3;122(1):253-66. Erratum in: J Clin Invest. 2012 Feb 1;122(2):782.
2. Alexeyenko A, Lee W, Pernemalm M, Guegan J, Dessen P, Lazar V, Lehtiö J, Pawitan Y. Network enrichment analysis: extension of gene set enrichment analysis to gene networks, BMC Bioinformatics 2012, 13:226.
3. Bergmann TK, Brasch Andersen C, Gréen H, Mirza MR, Skougaard K, Wihl J, Keldsen N, Damkier P, Peterson C, Vach W, Brøsen K. Impact of ABCB1 variants on neutrophil depression: a prospective pharmacogenomic study of paclitaxel in 92 women with ovarian cancer. Basic & Clinical Pharmacology & Toxicology, 2012, 110 (2), 199–204.
4. Borst P. Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? Open Biol. 2012 May;2(5):120066.
5. Cossa G, Gatti L, Cassinelli G, Lanzi C, Zaffaroni N, Perego P. Modulation of Sensitivity to Antitumor Agents by Targeting the MAPK Survival Pathway. Current Pharmaceutical Design, in press.
6. D’Arcy P and Linder S (2012) Proteasome deubiquitinating activity as a novel target for cancer therapy. International Journal of Biochemistry & Cell Biology, Epub Jul 17.
7. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov. 2012 Feb 3;11(3):215-33.
8. Ganuza M, Sáiz-Ladera C, Cañamero M, Gómez G, Schneider R, Blasco MA, Pisano D, Paramio JM, Santamaría D, Barbacid M. Genetic inactivation of Cdk7 leads to cell cycle arrest and induces premature aging due to adult stem cell exhaustion. EMBO J. 2012 Apr 13;31(11):2498-510.
9. Gréen H, Suleman Khan M, Jakobsen-Falk I, Åvall-Lundqvist E, Peterson C. The impact of CYP3A5*3 and CYP2C8 HapC on paclitaxel and carboplatin induced myelosuppression in ovarian cancer patients. Journal of Pharmaceutical Sciences, 2011, 100 (10), 4205–4209.
10. Hasmats J, Kupershmidt I, Lundeberg J, Gréen H. Identification of candidate SNPs for drug induced toxicity from differentially expressed genes in associated tissues. Manuscript accepted in GENE.
11. Hasmats, J., et al., Validation of whole genome amplification for analysis of the p53 tumor suppressor gene in limited amounts of tumor samples. Biochemical and biophysical research communications, 2012. 425(2): p. 379-83.
12. Hernlund E, Olofsson MH, Fayad W, Fryknäs M, Lesiak-Mieczkowska K, Zhang X, Brnjic S, Schmidt V, D’Arcy P, Sjöblom T, De Milito A, Larsson R and Linder S. (2012) The PI3K/mTOR inhibitor NVP-BEZ235 is effective in inhibiting regrowth of tumor cells after cytotoxic therapy. Eur J Cancer, 48:396-406.
13. Higgins G, Roper KM, Watsona IJ, Blackhall FH, Rom WN, Pass HI, Ainscough JF-X, Coverley D. Variant Ciz1 is a circulating biomarker for early stage lung cancer. PNAS in press.
14. Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, Priest LJ, Greystoke A, Zhou C, Morris K, Ward T, Blackhall FH, Dive C. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol. 2012 Feb 10;30(5):525-32. Epub 2012 Jan 17. PubMed PMID: 22253462.
15. Jemaà M, Galluzzi L, Kepp O, Boilève A, Lissa D, Senovilla L, Harper F, Pierron G, Berardinelli F, Antoccia A, Castedo M, Vitale I, Kroemer G. Preferential killing of p53-deficient cancer cells by reversine. Cell Cycle. 2012 Jun 1;11(11):2149-58.
16. Jemaà M, Vitale I, Kepp O, Berardinelli F, Galluzzi L, Senovilla L, Mariño G, Malik SA, Rello-Varona S, Lissa D, Antoccia A, Tailler M, Schlemmer F, Harper F,  Pierron G, Castedo M, Kroemer G. Selective killing of p53-deficient cancer cells  by SP600125. EMBO Mol Med. 2012 Jun;4(6):500-14.
17. Krebs MG, Hou JM, Sloane R, Lancashire L, Priest L, Nonaka D, Ward TH, Backen A, Clack G, Hughes A, Ranson M, Blackhall FH, Dive C. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J Thorac Oncol. 2012 Feb;7(2):306-15. PubMed PMID: 22173704.
18. Ladoire S, Chaba K, Martins I, Sukkurwala AQ, Adjemian S, Michaud M, Poirier-Colame V, Andreiuolo F, Galluzzi L, White E, Rosenfeldt M, Ryan KM, Zitvogel L, Kroemer G. Immunohistochemical detection of cytoplasmic LC3 puncta in human cancer specimens. Autophagy. 2012 Aug 1;8(8). [Epub ahead of print]
19. Latypov VF, Tubbs JL, Watson AJ, Marriott AS, McGown G, Thorncroft M, Wilkinson OJ, Senthong P, Butt A, Arvai AS, Millington CL, Povey AC, Williams DM, Santibanez-Koref MF, Tainer JA, Margison GP. Atl1 regulates choice between global genome and transcription-coupled repair of O6-alkylguanines. Mol Cell. 2012 Jul 13;47(1):50-60.
20. Laurent-Matha V, Huesgen PF, Masson O, Derocq D, Prébois C, Gary-Bobo M, Lecaille F, Rebière B, Meurice G, Oréar C, Hollingsworth RE, Abrahamson M, Lalmanach G, Overall CM and Liaudet-Coopman E. (2012) Proteolysis of cystatin C by cathepsin D in the breast cancer microenvironment. FASEB J. Aug 16. [Epub ahead of print]
21. Marino ML, Pellegrini P, Di Lernia G, Djavaheri-Mergny M, Brnjic S, Zhang X, Hägg M, Linder S, Fais S, Codogno P, De Milito A. Autophagy Is a Protective Mechanism for Human Melanoma Cells under Acidic Stress. J Biol Chem. 2012 Aug 31;287(36):30664-76. Epub 2012 Jul 3.
22. Martins I, Michaud M, Sukkurwala AQ, Adjemian S, Ma Y, Shen S, Kepp O, Menger L, Vacchelli E, Galluzzi L, Zitvogel L, Kroemer G. Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death. Autophagy. 2012 Mar 1;8(3). [Epub ahead of print]
23. Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Shen S, Yamazaki T, Sukkurwala AQ, Michaud M, Mignot G, Schlemmer F, Sulpice E, Locher C, Gidrol X, Ghiringhelli F, Modjtahedi N, Galluzzi L, André F, Zitvogel L, Kepp O, Kroemer G. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med. 2012 Jul 18;4(143):143ra99.
24. Michaud M, Sukkurwala AQ, Martins I, Shen S, Zitvogel L, Kroemer G. Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39. Oncoimmunology. 2012 May 1;1(3):393-395.
25. Moro M, Bertolini G, Tortoreto M, Pastorino U, Sozzi G, Roz L. Patient-derived xenografts of non small cell lung cancer: resurgence of an old model for investigation of modern concepts of tailored therapy and cancer stem cells. Biomed Biotechnol. 2012;2012:568567. Epub 2012 Apr 4.
26. Navas C, Hernández-Porras I, Schuhmacher AJ, Sibilia M, Guerra C, Barbacid M. EGF Receptor signaling is essential for K-Ras ONCOGENE-driven pancreatic ductal adenocarcinoma. Cancer Cell (in press).
27. Perotti V, Baldassari P, Bersani I, Molla A, Vegetti C, Tassi E, Col JD, Dolcetti R, Anichini A, Mortarini R. NFATc2 Is a Potential Therapeutic Target in Human Melanoma. J Invest Dermatol. 2012 Jun 21. doi: 10.1038/jid.2012.179. [Epub ahead of print].
28. Rottenberg S, Borst P. Drug resistance in the mouse cancer clinic. Drug Resist Updat. 2012 Feb-Apr;15(1-2):81-9.
29. Rottenberg S, Vollebergh MA, de Hoon B, de Ronde J, Schouten PC, Kersbergen A, Zander SA, Pajic M, Jaspers JE, Jonkers M, Lodén M, Sol W, van der Burg E, Wesseling J, Gillet JP, Gottesman MM, Gribnau J, Wessels L, Linn SC, Jonkers J, Borst P. Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors. Cancer Res. 2012 May 1;72(9):2350-61.
30. Salim H, Akbar NS, Zong D, Vaculova AH, Lewensohn R, Moshfegh A, Viktorsson K, Zhivotovsky B. miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence. Br J Cancer. 2012 Aug 28. doi: 10.1038/bjc.2012.382. [Epub ahead of print]
31. Surova, C., Akbar, N.S., and Zhivotovsky, B. Knock-down of core proteins regulating microRNA biogenesis has no effect on sensitivity of lung cancer cells to ionizing radiation. PLoS ONE, 2012: 7(3):e33134.
32. Tassi E, Zanon M, Vegetti C, Molla A, Bersani I, Perotti V, Pennati M, Zaffaroni N, Milella M, Ferrone S, Carlo-Stella C, Gianni AM, Mortarini R, Anichini A. Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways. Clin Cancer Res. 2012 Jun 15;18(12):3316-27.
33. Uboldi S, Bernasconi S, Romano M, Marchini S, Fuso Nerini I, Damia G, Ganzinelli M, Marangon E, Sala F, Clivio L, Chiorino G, Di Giandomenico S, Rocchi M, Capozzi O, Margison GP, Watson AJ, Caccuri AM, Pastore A, Fossati A, Mantovani R, Grosso F, Tercero JC, Erba E, D'Incalci M. Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents. Int J Cancer. 2012 Jul 1;131(1):59-69.
34. Vacchelli E, Galluzzi L, Rousseau V, Rigoni A, Tesniere A, Delahaye N, Schlemmer FD, Menger L, Sukkurwala AQ, Adjemian S, Martins I, Michaud M, Dunant A, Kepp O, Brambilla E, Soria JC, Zitvogel L, Kroemer G. Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer. Oncoimmunology. 2012 May 1;1(3):271-278.
35. Vaughan AA, Dunn WB, Allwood JW, Wedge DC, Blackhall FH, Whetton AD, Dive C, Goodacre R. Liquid Chromatography-Mass Spectrometry Calibration Transfer and Metabolomics Data Fusion. Analytical Chemistry in Press.
36. Warmoes M, Jaspers JE, Pham TV, Piersma SR, Oudgenoeg G, Massink MP, Waisfisz Q, Rottenberg S, Boven E, Jonkers J, Jimenez CR. Proteomics of Mouse BRCA1-deficient Mammary Tumors Identifies DNA Repair Proteins with Potential Diagnostic and Prognostic Value in Human Breast Cancer. Mol Cell Proteomics. 2012 Jul;11(7):M111.013334.
37. Yao Z, Jones AW, Fassone E, Sweeney MG, Lebiedzinska M, Suski JM, Wieckowski MR, Tajeddine N, Hargreaves IP, Yasukawa T, Tufo G, Brenner C, Kroemer G, Rahman  S, Szabadkai G. PGC-1β mediates adaptive chemoresistance associated with mitochondrial DNA mutations. Oncogene. 2012 Jul 9. doi: 10.1038/onc.2012.259. [Epub ahead of print]
38. Zander SA, Kersbergen A, Sol W, Gonggrijp M, van de Wetering K, Jonkers J, Borst P, Rottenberg S. Lack of ABCG2 Shortens Latency of BRCA1-Deficient Mammary Tumors and This Is Not Affected by Genistein or Resveratrol. Cancer Prev Res (Phila). 2012 Aug;5(8):1053-60.
39. Zander SA, Sol W, Greenberger L, Zhang Y, van Tellingen O, Jonkers J, Borst P, Rottenberg S. EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors. PLoSOne (in press).

2011

1. Beekman CA, Buckle T, van Leeuwen AC, Valdés Olmos RA, Verheij M, Rottenberg S, van Leeuwen FW. Questioning the value of (99m)Tc-HYNIC-annexin V based response monitoring after docetaxel treatment in a mouse model for hereditary breast cancer. 2011. Appl. Radiat. Isot. 69(4): 656-62.
2. Bergmann TK, C Brasch-Andersen, H Gréen, MR Mirza, RS Pedersen, F Nielsen, K Skougaard, J Wihl, N Keldsen, P Damkier, LE Friberg, C Peterson, W Vach, MO Karlsson and K Brosen. Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. 2011. In Press The Pharmacogenomics Journal. [Epub ahead of print] Apr 6th 2010.
3. Bergmann TK, H Gréen, C Brasch-Andersen, MR Mirza, J Herrstedt, B Hølund, P Damkier, W Vach, K Brosen and C Peterson. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity in ovarian cancer. 2011. European J. Clinical Pharmacology. DOI: 10.1007/s00228-011-1007-6
4. Blasco RB, Francoz S, Santamaría D, Cañamero M, Dubus P, Charron J, Baccarini M, Barbacid M. c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell. 2011 May 17;19(5):652-63.
5. Boehrer S, Galluzzi L, Lainey E, Bouteloup C, Tailler M, Harper F, Pierron G, Adès L, Thépot S, Sébert M, Gardin C, de Botton S, Fenaux P, Kroemer G. Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia. Cell Cycle. 2011 Sep 15;10(18):3168-75.
6. Bouwhuis MG, Collette S, Suciu S, de Groot ER, Kruit WH, Ten Hagen TL, Aarden LA, Eggermont AM, Swaak AJ; EORTC Melanoma Group. Changes of ferritin and CRP levels in melanoma patients treated with adjuvant interferon-α (EORTC 18952) and prognostic value on treatment outcome. Melanoma Res. 2011 Aug;21(4):344-51.
7. Büttner S, Ruli D, Vögtle FN, Galluzzi L, Moitzi B, Eisenberg T, Kepp O, Habernig L, Carmona-Gutierrez D, Rockenfeller P, Laun P, Breitenbach M, Khoury C, Fröhlich KU, Rechberger G, Meisinger C, Kroemer G, Madeo F. A yeast BH3-only protein mediates the mitochondrial pathway of apoptosis. EMBO J. 2011 Jun 14;30(14):2779-92.
8. D’Arcy P, Brnjic S, Olofsson MH, Fryknäs M, Lindsten K, De Cesare M, Perego P, Sadeghi B, Hassan M, Larsson R and Linder S (2011) Inhibition of proteasome deubiquitinating activity as a novel cancer therapy. Nature Medicine 17: 1636-1640.
9. De Petris L., Brandén E., Herrmann R., Chavez Sanchez B., Koyi H., Linderholm B, Lewensohn R, Linder  S., Lehtiö J. Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small-cell lung cancer. 2011. Eur. J. Cancer. 47(1):131-7.
10. Drost R, Bouwman P, Rottenberg S, Boon U, Schut E, Klarenbeek S, Klijn C, van der Heijden I, van der Gulden H, Wientjens E, Pieterse M, Catteau A, Green P, Solomon E, Morris JR, Jonkers J. BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell. 2011 Dec 13;20(6):797-809.
11. Fayad W, Rickardson L, Haglund C, Olofsson MH, D'Arcy P, Larsson R, Linder S, Fryknäs M. (2011). Identification of Agents that Induce Apoptosis of Multicellular Tumour Spheroids: Enrichment for Mitotic Inhibitors with Hydrophobic Properties. Chem. Biol. Drug Des. 78:547-57.
12. Forshed J, Johansson HJ, Pernemalm M, Branca RM, Sandberg A, Lehtiö J. Enhanced information output from shotgun proteomics data by protein quantification and peptide quality control (PQPQ). Mol Cell Proteomics. 2011 Jul 6.
13. Galluzzi L, Morselli E, Kepp O, Vitale I, Younes AB, Maiuri MC, Kroemer G. Evaluation of rapamycin-induced cell death. Methods Mol Biol. 2012;821:125-69.
14. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene. 2012 Apr 12;31(15):1869-83.
15. Guerra C, Collado M, Navas C, Schuhmacher AJ, Hernández-Porras I, Cañamero M, Rodriguez-Justo M, Serrano M, Barbacid M. Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell. 2011 Jun 14;19(6):728-39.
16. Hou JM, M. Krebs, T. Ward, R. Sloane, L. Priest, A. Hughes, G. Clack, M. Ranson, F. Blackhall, C. Dive. Circulating Tumor Cells as a Window on Metastasis Biology in Lung Cancer.  2011. Am. J. Pathol. 178 (3): 989-996.
17. Kaminskyy, V., Abdi, A., and Zhivotovsky, B. A quantitative assay for the monitoring of autophagosome accumulation in different phases of the cell cycle. 2011. Autophagy. 7: 83-90.
18. Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, Greystoke A, Ward TH, Ferraldeschi R, Hughes A, Clack G, Ranson M, Dive C, Blackhall FH. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol. 2011 Apr 20;29(12):1556-63. Epub 2011Mar 21. PubMed PMID: 21422424.
19. Lainey E, Thépot S, Bouteloup C, Sébert M, Adès L, Tailler M, Gardin C, de Botton S, Baruchel A, Fenaux P, Kroemer G, Boehrer S. Tyrosine kinase inhibitors  for the treatment of acute myeloid leukemia: delineation of anti-leukemic mechanisms of action. Biochem Pharmacol. 2011 Nov 15;82(10):1457-66.
20. Lopez S, Margison GP, Stanley McElhinney R, Cordeiro A, McMurry TB, Rozas I. Towards more specific O6-Methylguanine-DNA methyltransferase (MGMT) inactivators. 2011. Bioorganic & Medicinal Chemistry. 19(5):1658-65.
21. Ma, Y., Aymeric, L., Locher, C., Kroemer, G., and Zitvogel, L. The dendritic cell-tumor cross-talk in cancer. 2011. Curr Opin Immunol. 23(1): 146-52.
22. Malik SA, Orhon I, Morselli E, Criollo A, Shen S, Mariño G, BenYounes A, Bénit P, Rustin P, Maiuri MC, Kroemer G. BH3 mimetics activate multiple pro-autophagic pathways. Oncogene. 2011 Sep 15;30(37):3918-29.
23. Malik SA, Shen S, Mariño G, BenYounès A, Maiuri MC, Kroemer G. BH3 mimetics reveal the network properties of autophagy-regulatory signaling cascades. Autophagy. 2011 Aug;7(8):914-6.
24. Martins, I., Kepp, O., Schlemmer, F., Adjemian, S., Tailler, M., Shen, S., Michaud, M., Menger, L., Gdoura, A., Tajeddine, N., Tesniere, A., Zitvogel, L., and Kroemer, G. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. 2011. Oncogene. 30: 1147–1158.
25. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S,  Kepp O, Scoazec M, Mignot G, Rello-Varona S, Tailler M, Menger L, Vacchelli E, Galluzzi L, Ghiringhelli F, di Virgilio F, Zitvogel L, Kroemer G. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science. 2011 Dec 16;334(6062):1573-7
26. Orrenius, S., Nicotera, P., and Zhivotovsky, B. Cell death mechanisms and their implications in toxicology. 2011. Toxicol. Sci. 119: 3-19.
27. Perego M, Alison MR, Mariani L, Rivoltini L, Castelli C. Spheres of influence in cancer stem cell biology. 2011. J. Invest Dermatol. 131(2): 546-7.
28. Shen S, Kepp O, Michaud M, Martins I, Minoux H, Métivier D, Maiuri MC, Kroemer RT, Kroemer G. Association and dissociation of autophagy, apoptosis and necrosis by systematic chemical study. Oncogene. 2011 Nov 10;30(45):4544-56
29. Spugnini EP, Baldi A, Buglioni S, Carocci F, Milesi de Bazzichini G, Betti G, Pantaleo I, Menicagli F, Citro G, Fais S  (2011) Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors. J Transl Med. 9: 221.
30. Ståhl S, Mm Branca R, Efazat G, Ruzzene M, Zhivotovsky B, Lewensohn R, Viktorsson K, Lehtiö J. Phosphoproteomic profiling of NSCLC cells reveals that ephrin B3 regulates pro-survival signaling through Akt1-mediated phosphorylation of the EphA2 receptor. J Proteome Res. 2011 May 6;10(5):2566-78.
31. Tailler M, Senovilla L, Lainey E, Thépot S, Métivier D, Sébert M, Baud V, Billot K, Fenaux P, Galluzzi L, Boehrer S, Kroemer G, Kepp O. Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia. Oncogene. 2012 Jul 26;31(30):3536-46.
32. Thépot S, Lainey E, Cluzeau T, Sébert M, Leroy C, Adès L, Tailler M, Galluzzi L, Baran-Marszak F, Roudot H, Eclache V, Gardin C, de Botton S, Auberger P, Fenaux P, Kroemer G, Boehrer S. Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia. Cell Cycle. 2011 Jul 15;10(14):2323-30.
33. Urosevic J, Sauzeau V, Soto-Montenegro ML, Reig S, Desco M, Wright EM, Cañamero M, Mulero F, Ortega S, Bustelo XR, Barbacid M. Constitutive activation of B-Raf in the mouse germ line provides a model for human cardio-facio-cutaneous syndrome. Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5015-20.
34. Usmanova, N., Tomilin, N., Zhivotovsky, B., and Kropotov, A. Transcription factor GABP/NRF-2 controlling biogenesis of mitochondria regulates basal expression of peroxiredoxin V but the mitochondrial function of peroxiredoxin V is dispensable in the dog. 2011. Biochimie. 93: 306-313.
35. Vergani E, Vallacchi V, Frigerio S, Deho P, Mondellini P, Perego P, Cassinelli G, Lanzi C, Testi MA, Rivoltini L, Bongarzone I, Rodolfo M. Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. Neoplasia. 2011; 13(12):1132-42.
36. Vitale I, Galluzzi L, Castedo M, Kroemer G. Mitotic catastrophe: a mechanism  for avoiding genomic instability. Nat Rev Mol Cell Biol. 2011 Jun;12(6):385-92.
37. Wedge DC, Allwood JW, Dunn W, Vaughan AA, Simpson K, Brown M, Priest L, Blackhall FH, Whetton AD, Dive C, Goodacre R. Is serum or plasma more appropriate for intersubject comparisons in metabolomic studies? An assessment in patients with small-cell lung cancer. Anal Chem. 2011 Sep 1;83(17):6689-97. Epub 2011 Aug 2. PubMed PMID: 21766834.
38. Wennberg BM, Baumann P, Gagliardi G, Nyman J, Drugge N, Hoyer M, Traberg A, Nilsson K, Morhed E, Ekberg L, Wittgren L, Lund JA, Levin N, Sederholm C, Lewensohn R, Lax I. NTCP modelling of lung toxicity after SBRT comparing the universal survival curve and the linear quadratic model for fractionation correction. 2011. Acta Oncol. [Epub ahead of print] Jan 4th 2011.
39. Zong, D; Hååg, P; Yakymovych, I; Lewensohn, R; Viktorsson, K. Chemosensitization by phenothiazines in human lung cancer cells: impaired resolution of γH2AX and increased oxidative stress elicit apoptosis associated with lysosomal expansion and intense vacuolation, Cell death & disease, EISSN 2041-4889, 2011, Volym 2, p. e181

2010

1.  Aymeric, L., Apetoh, L., Ghiringhelli, F., Tesniere, A., Martins, I., Kroemer, G., Smyth, M. J., and Zitvogel, L. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. 2010. Cancer Res. 70: 855-858.
2. Beretta G.L., V. Benedetti, G. Cossa, Y.G.A. Assaraf , E. Bram, L Gatti, E. Corna, N. Carenini, D. Colangelo, S.B. Howell, F. Zunino and P. Perego. Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin. 2010. Biochem Pharmacol.79(8): 1108-17.
3. Bertolini G, Gatti L, Roz L. The "stem" of chemoresistance. 2010. Cell Cycle. 4: 628-9.
4. Borst P, Wessels L. Do predictive signatures really predict response to cancer chemotherapy? 2010. Cell Cycle. 9(24): 4836-40.
5. Bouwhuis MG , S Suciu, ATestori, WH Kruit, F Salès, P Patel, CJ Punt, M Santinami, A Spatz,TLM ten Hagen, AMM Eggermont, for the EORTC Melanoma Group. Prognostic significance of autoantibodies in melanoma stage III patients in the EORTC 18991 phase III randomized trial comparing adjuvant treatment with pegylated interferon a2b vs observation. 2010. J. Clin. Oncol. 28(14): 2460-2466.
6. Bozhkov, P.V., Smertenko, A.P., and Zhivotovsky, B. Aspasing out metacaspases and caspases: Proteases of many trades. 2010. Science Signal. 3 (152): pe48.
7. Calzone, L., Tournier, L., Fourquet, S., Thieffry, D., Zhivotovsky, B., Barillot, E., and Zinovyev, A. Mathematical modelling of cell-fate decision in response to death receptor engagement. 2010. PLoS Comput. Biol. 6:e1000702.
8. Castedo, M., Vitale, I., and Kroemer, G. A novel source of tetraploid cancer cell precursors: telomere insufficiency links aging to oncogenesis. 2010. Oncogene 29: 5869-5872.
9. Conforti, R., Ma, Y., Morel, Y., Paturel, C., Terme, M., Viaud, S., Ryffel, B., Ferrantini, M., Uppaluri, R., Schreiber, R., Combadiere, C., Chaput, N., Andre, F., Kroemer, G., and Zitvogel, L. Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. 2010. Cancer Res. 70: 490-500.
10. Criollo A, Senovilla L, Kepp O, Authier H, Shen S, Maiuri MC, Tasdemir E, Tallier M, Morselli E, Galluzzi L, Delahaye N, Tesniere A, Commo F, Harper F, Vicencio JM, Ben Younes A, Pierron G, Lavandero S,  Zitvogel L, Israel A, Baud V, Kroemer G. The IKK complex contributes to the induction of autophagy. 2010. EMBO Journal. 29: 619 – 631.
11. De Petris L, Pernemalm M, Elmberger G, Bergman P, Orre L, Lewensohn R, Lehtiö J. A novel method for sample preparation of fresh lung cancer tissue for proteomics analysis by tumor cell enrichment and removal of blood contaminants. 2010. Proteome Sci. 8: 9.
12. Fulda, S., Galluzzi, L., and Kroemer, G. Targeting mitochondria for cancer therapy. 2010. Nat. Rev. Drug Discov. 9: 447-464.
13. Galluzzi L, Morselli E, Kepp O, Vitale I, Rigoni A, Vacchelli E, Michaud M, Zischka H, Castedo M, Kroemer G. Mitochondrial gateways to cancer. 2010. Mol Aspects Med. 31(1): 1-20.
14. Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Servant N, Paccard C, Hupé P, Robert T. Ripoche H. Lazar V, Harel-Bellan A, Dessen P, Barillot E, Kroemer G. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. 2010. Cancer Res. 70(5):1793-1803.
15. Galluzzi, L., Kepp, O., Morselli, E., Vitale, I., Senovilla, L., Pinti, M., Zitvogel, L., and Kroemer, G. Viral strategies for the evasion of immunogenic cell death. 2010. J. Intern. Med. 267: 526-542.
16. Galluzzi, L., Morselli, E., Kepp, O., Maiuri, M. C., and Kroemer, G. Defective autophagy control by the p53 rheostat in cancer. 2010. Cell Cycle. 9: 250-255.
17. Galluzzi, L., Morselli, E., Kepp, O., Vitale, I., Rigoni, A., Vacchelli, E., Michaud, M., Zischka, H., Castedo, M., and Kroemer, G. Mitochondrial gateways to cancer. 2010. Mol. Aspects Med. 31: 1-20.
18. Galluzzi, L., Morselli, E., Vitale, I., Kepp, O., Senovilla, L., Criollo, A., Servant, N., Paccard, C., Hupe, P., Robert, T., Ripoche, H., Lazar, V., Harel-Bellan, A., Dessen, P., Barillot, E., and Kroemer, G. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. 2010. Cancer Res. 70: 1793-1803.
19. Gasparini P, Bertolini G, Binda M, Magnifico A, Albano L, Tortoreto M, Pratesi G, Facchinetti F, Abolafio G, Roz L, Tagliabue E, Daidone MG, Sozzi G. Molecular cytogenetic characterization of stem-like cancer cells isolated from established cell lines. 2010. Cancer Lett. 296: 206-215.
20. Gogvadze, V., Norberg, E., Orrenius, S., and Zhivotovsky, B. Involvement of Ca²⁺ and ROS in α-tocopheryl succinate-induced mitochondrial permeabilization. 2010. Int. J. Cancer. 127: 1823-1832.
21. Gogvadze, V., Zhivotovsky, B., and Orrenius, S. The Warburg effect and mitochondrial stability in cancer cells. 2010. Mol. Aspects Med. 31: 60-74.
22. Issaeva N, Thomas HD, Djureinovic T, Jaspers JE, Stoimenov I, Kyle S, Pedley N, Gottipati P, Zur R, Sleeth K, Chatzakos V, Mulligan EA, Lundin C, Gubanova E, Kersbergen A, Harris AL, Sharma RA, Rottenberg S, Curtin NJ, Helleday T. 6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. 2010. Cancer Res. 70(15): 6268-76.
23. Kaminskyy, V., and Zhivotovsky, B. To kill or be killed: how viruses interact with the cell death machinery. 2010. J. Intern. Med. 267: 473-482.
24. Kroemer, G. Tetraploid cancer cell precursors. 2010. Nat. Rev. Mol. Cell Biol. 11: 539.
25. Kroemer, G., and White, E. Autophagy for the avoidance of degenerative, inflammatory, infectious, and neoplastic disease. 2010. Curr. Opin. Cell Biol. 22: 121-123.
26. Krogh M, I Christensen, MG Bouwhuis, JS Johansen, H Schmidt, J Hansson, S Aamdal, A Testori, AMM Eggermont, L Bastholt, The Nordic Melanoma Group and EORTC Melanoma Group. Prognostic value of serum YKL-40 in stage IIB-III melanoma patients receiving adjuvant interferon therapy. 2010. J Clin Oncol (proceedings ASCO 2010): (28)15_suppl 8587.
27. Lehtiö J, De Petris L. Lung cancer proteomics, clinical and technological considerations. 2010. J Proteomics. 73(10):1851-63.
28. Locher, C., Conforti, R., Aymeric, L., Ma, Y., Yamazaki, T., Rusakiewicz, S., Tesniere, A., Ghiringhelli, F., Apetoh, L., Morel, Y., Girard, J. P., Kroemer, G., and Zitvogel, L. Desirable cell death during anticancer chemotherapy. 2010. Ann. NY Acad. Sci. 1209: 99-108.
29. M Perego, M Tortoreto, G Tragni, L Mariani, P Deho, A Carbone, M Santinami, R Patuzzo, P Della Mina, A Villa, G Pratesi, G Cossa, P Perego, M G Daidone, M.R. Alison, G Parmiani, L Rivoltini, C Castelli. Heterogeneous phenotype of human melanoma cells with in vitro and in vivo features of tumor initiating cells. 2010. J. Invest. Dermatol. 130(7):1877-1886.
30. M. Puyol, A. Martín, P. Dubus, F. Mulero, P. Pizcueta, G. Khan, C. Guerra, D. Santamaría and M. Barbacid. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non small cell lung carcinoma. 2010. Cancer Cell. 18:63-73.
31. Ma, Y., Kepp, O., Ghiringhelli, F., Apetoh, L., Aymeric, L., Locher, C., Tesniere, A., Martins, I., Ly, A., Haynes, N. M., Smyth, M. J., Kroemer, G., and Zitvogel, L. Chemotherapy and radiotherapy: cryptic anticancer vaccines. 2010. Semin. Immunol. 22: 113-124.
32. Maiuri, M. C., Galluzzi, L., Morselli, E., Kepp, O., Malik, S. A., and Kroemer, G. Autophagy regulation by p53. 2010. Curr Opin Cell Biol. 22: 181-185.
33. Marino, G., and Kroemer, G. Ammonia: a diffusible factor released by proliferating cells that induces autophagy. 2010. Sci. Signal 3: pe19.
34. Morselli, E., Galluzzi, L., Kepp, O., Marino, G., Michaud, M., Vitale, I., Maiuri, M. C., and Kroemer, G. Oncosuppressive Functions of Autophagy. 2010. Antioxid Redox Signal. [Epub ahead of print].
35. Morselli, E., Maiuri, M. C., Markaki, M., Megalou, E., Pasparaki, A., Palikaras, K., Criollo, A., Galluzzi, L., Malik, S. A., Vitale, I., Michaud, M., Madeo, F., Tavernarakis, N., and Kroemer, G. The life span-prolonging effect of sirtuin-1 is mediated by autophagy. 2010. Autophagy 6: 186-188.
36. Nikpour, M., Pellagatti, A., Liu, A., Karimi, M., Malcovati, L., Gogvadze, V., Forsblom, A-M., Wainscoat, J.S., Cazzola, M., Zhivotovsky, B., Grandien, A., Boultwood, J., Hellström-Lindberg. E. Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of G-CSF. 2010. Br. J. Hematol. 149: 844-854.
37. Norberg E, Gogvadze V, Vakifahmetoglu H, Orrenius S, Zhivotovsky B. Oxidative modification sensitizes mitochondrial apoptosis-inducing factor to calpain-mediated processing. 2010. Free Radic. Biol. Med. 48(6):791-7.
38. Norberg, E., Gogvadze, V., Vakifahmetoglu, H., Orrenius, S., and Zhivotovsky, B. Oxidative modification sensitizes mitochondrial apoptosis-inducing factor to calpain-mediated processing. 2010. Free Radic. Biol. Med. 48: 791-797.
39. Norberg, E., Karlsson, M., Korenovska, O., Szydlowski, S., Silberberg, G., Uhlén, P., Orrenius, S., and Zhivotovsky, B. Critical role for hyperpolarization-activated cyclic nucleotide-gated channel 2 in the AIF-mediated apoptosis. 2010. EMBO J. 29: 3869-3878.
40. Norberg, E., Orrenius, S., and Zhivotovsky, B.  Mitochondrial regulation of cell death –processing of Apoptosis-Inducing Factor (AIF). 2010. Biochem. Biophys. Res. Commun. 396: 95-100.
41. Nyman, U., Muppani, N.R., Zhivotovsky, B., and Joseph, B. Hsp72 mediates TAp73α anti-apoptotic effects in small cell lung carcinoma cells. 2010. J. Cell. Mol. Med. DOI: 10.1111/j.1582-4934.2010.01166.x.
42. Pajic M, Kersbergen A, van Diepen F, Pfauth A, Jonkers J, Borst P, Rottenberg S. Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo. 2010. Cell Cycle 9(18): 3780-91.
43. Perego M, Tortoreto M, Tragni G, Mariani L, Deho P, Carbone A, Santinami M, Patuzzo R, Mina PD, Villa A, Pratesi G, Cossa G, Perego P, Daidone MG, Alison MR, Parmiani G, Rivoltini L, Castelli C. Heterogeneous phenotype of human melanoma cells with in vitro and in vivo features of tumor-initiating cells. 2010. J. Invest. Dermatol. 130(7):1877-86.
44. Perego P, Cossa G, Zuco V, Zunino F. Modulation of cell sensitivity to antitumor agents by targeting survival pathways. 2010. Biochem Pharmacol. 80:1459-65.
45. Pisano C., Vesci L, Milazzo FM, Guglielmi MB, Foderà R, Barbarino M, D'Incalci M, Zucchetti M, Petrangolini G, Tortoreto M, Perego P, Zuco V, Orlandi A, Passeri D, Carminati P, Cavazza C, Zunino F. Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-L-carnitine. 2010. Clin Cancer Res., 16: 3944-53.
46. Pizzamiglio S, G. Cossa, L. Gatti, G.L. Beretta, E. Corna, S. Tinelli, P. Verderio and P. Perego. Simultaneous confidence intervals to compare gene expression profiles using ABC transporter TaqMan microfluidic cards. 2010. Oncol. Rep. 23(3):853-60.
47. S.A.L. Zander, A. Kersbergen, E. van der Burg, N. de Water, O. van Tellingen, S. Gunnarsdottir, J.E. Jaspers, A.O.H. Nygren, J. Jonkers, P. Borst, S. Rottenberg. Sensitivity and acquired resistance of BRCA1; P53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. 2010. Cancer Res. 70(4):1700-10.
48. Shen, S., Kepp, O., Martins, I., Vitale, I., Souquere, S., Castedo, M., Pierron, G., and Kroemer, G. Defective autophagy associated with LC3 puncta in epothilone-resistant cancer cells. 2010. Cell Cycle 9: 377-383.
49. Tesniere A, Schlemmer F, Kepp O, Rero AL, Apetoh L, Michaud M, Boige V, Pignon JP, Puig P, Garrido C, Zitvogel L, Kroemer G. Immunogenic death of colon cancer cells treated with oxaliplatin. 2010. Oncogene 29: 482-491.
50. Tesniere, A., Abermil, N., Schlemmer, F., Casares, N., Kepp, O., Pequignot, M., Michaud, M., Martins, I., Senovilla, L., Zitvogel, L., and Kroemer, G. In vivo depletion of T lymphocyte-specific transcription factors by RNA interference. 2010. Cell Cycle 9: 2830-2835.
51. Tesniere, A., Schlemmer, F., Boige, V., Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apetoh, L., Barault, L., Mendiboure, J., Pignon, J. P., Jooste, V., van Endert, P., Ducreux, M., Zitvogel, L., Piard, F., and Kroemer, G. Immunogenic death of colon cancer cells treated with oxaliplatin. 2010. Oncogene. 29: 482-491.
52. Vaculova, A., Kaminskyy, V., Jalalvand, E., Surova, O., and Zhivotovsky, B. Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL. 2010. Mol Cancer. 91: 87.
53. Vakifahmetoglu-Norberg H, Zhivotovsky B. The unpredictable caspase-2: what can it do? 2010. Trends Cell Biol. 20(3): 150-9.
54. Vakifahmetoglu-Norberg, H., and Zhivotovsky, B. The unpredictable caspase-2: What can it do? 2010. Trends Cell Biol. 20: 150-159.
55. Vallacchi V, Daniotti M, De Filippo A, Rivoltini L, Perbal B and Rodolfo M. CCN3 promotes melanoma progression by regulating integrin expression, adhesion and apoptosis induced by cytotoxic drugs. 2010. CCN proteins in health and disease 205-211. DOI: 10.1007/978-90-481-3779-4_15.
56. Vitale, I., Galluzzi, L., Senovilla, L., Criollo, A., Jemaa, M., Castedo, M., and Kroemer, G. Illicit survival of cancer cells during polyploidization and depolyploidization. 2010. Cell Death Differ. [Epub ahead of print]. Doi: 10.1038/cdd.2010.145.
57. Vitale, I., Senovilla, L., Jemaa, M., Michaud, M., Galluzzi, L., Kepp, O., Nanty, L., Criollo, A., Rello-Varona, S., Manic, G., Metivier, D., Vivet, S., Tajeddine, N., Joza, N., Valent, A., Castedo, M., and Kroemer, G. Multipolar mitosis of tetraploid cells: inhibition by p53 and dependency on Mos. 2010. EMBO J. 29:1272-1284.
58. Wickström M, Viktorsson K, Lundholm L, Aesoy R, Nygren H, Sooman L, Fryknäs M, Vogel LK, Lewensohn R, Larsson R, Gullbo J. The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan. 2010. Biochem Pharmacol. 79(9):1281-90.
59. Wolkenhauer O, Auffray C, Baltrusch S, Blüthgen N, Byrne H, Cascante M, Ciliberto A, Dale T, Drasdo D, Fell D, Ferrell JE Jr, Gallahan D, Gatenby R, Günther U, Harms BD, Herzel H, Junghanss C, Kunz M, van Leeuwen I, Lenormand P, Levi F, Linnebacher M, Lowengrub J, Maini PK, Malik A, Rateitschak K, Sansom O, Schäfer R, Schürrle K, Sers C, Schnell S, Shibata D, Tyson J, Vera J, White M, Zhivotovsky B, Jaster R. Systems biologists seek fuller integration of systems biology approaches in new cancer research programs. 2010. Cancer Res. 70(1):12-3.
60. Zhivotovsky, B. and Orrenius, S. Cell death mechanisms: cross-talk and role in disease. Experim. 2010. Cell Res. 316: 1347-1383.
61. Zhivotovsky, B., and Orrenius, S. Cell Cycle and Cell Death in Disease: past, present and future. 2010. J. Intern. Med. 268: 395-409.
62. Zitvogel, L., Kepp, O., Aymeric, L., Ma, Y., Locher, C., Delahaye, N. F., Andre, F., and Kroemer, G. Integration of host-related signatures with cancer cell-derived predictors for the optimal management of anticancer chemotherapy. 2010. Cancer Res. 70: 9538-9543.
63. Zitvogel, L., Kepp, O., Senovilla, L., Menger, L., Chaput, N., and Kroemer, G. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. 2010. Clin. Cancer Res. 16: 3100-3104.

2009

1. Berndtsson M, Beaujouin M, Mandic Havelka A, Larsson R, Westman J, Shoshan MC, Liaudet-Coopman E and Linder S. Induction of the lysosomal apoptosis pathway by inhibitors of the ubiquitin-proteasome system. Int J Cancer, 2009, 124, 1463-1469.
2. Bertolini G., L. Roz, P. Perego, M. Tortoreto, E. Fontanella, L. Gatti, G. Pratesi, A. Fabbri, F. Andriani, S. Tinelli, E. Roz, R. Caserini, S. Lo Vullo, T. Camerini, L. Mariani, D. Delia, E. Calabrò, U. Pastorino and G. Sozzi. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA, 2009, 106: 16281-16286.
3. Bouwhuis MG, Suciu S, Collette S, Aamdal S, Kruit WH, Bastholt L, Stierner U, Salès F, Patel P, Punt CJ, Hernberg M, Spatz A, ten Hagen TL, Hansson J, Eggermont AM; EORTC Melanoma Group and the Nordic Melanoma Group. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. J Natl Cancer Inst. 2009 Jun 16;101(12):869-77. (IF 15.9)
4. Cerqueira A, Santamaría D, Martínez-Pastor B, Cuadrado M, Fernández-Capetillo O, and Barbacid M. Overall Cdk activity modulates the DNA damage response in mammalian cells.J Cell Biol. 2009 Dec 14;187(6):773-80.
5. De Milito A, Canese R, Marino ML, et al. (2009) International Journal of Cancer 127, 207-19.
6. De Petris L., Orre LM., Kanter L., Pernemalm M., Koyi H., Lewensohn R., Lehtiö J. Tumor expression of S100A6 correlates with survival of patients with stage I non-small cell lung cancer. Lung Cancer. 2009 Mar; 63(3):410-7.
7. Fayad W, Fryknäs M, Brnjic S, Berndtsson M, Olofsson MH, Larsson R and Linder S. (2009) Identification of a novel topoisomerase inhibitor effective in multicellular spheroids and in cells overexpressing drug transporters. PLoS ONE 4, e7238.
8. Fulda S, Kroemer G. Targeting mitochondrial apoptosis by betulinic acid in human cancers. Drug Discov Today. 2009 Sep;14(17-18):885-90.
9. Gatti L., Beretta G.L., Cossa G., Zunino F., Perego P. ABC transporters as potential targets for modulation of drug resistance. Mini-Reviews in Medicinal Chemistry, 2009, 9:1102-1112.
10. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, Perfettini JL, Schlemmer F, Tasdemir E, Uhl M, Génin P, Civas A, Ryffel B, Kanellopoulos J, Tschopp J, André F, Lidereau R, McLaughlin NM, Haynes NM, Smyth MJ, Kroemer G*, Zitvogel L. (*Shared senior and co-corresponding author). Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med. 2009 Oct;15(10):1170-8.
11. Gogvadze V, Orrenius S, Zhivotovsky B. Mitochondria as targets for chemotherapy. Apoptosis. 2009 Apr;14(4):624-40.
12. Gogvadze V, Orrenius S, Zhivotovsky B. Semin. Mitochondria as targets for cancer chemotherapy. Cancer Biol. 2009 Feb;19(1):57-66.
13. Gogvadze V, Zhivotovsky B, Orrenius S. The Warburg effect and mitochondrial stability in cancer cells. Mol Aspects Med. 2009 Dec 6.
14. Hägg Olofsson M, Fayad W and Linder S. Use of caspase-cleaved CK18 as a pharmacodynamic marker for tumor response in human xenograft models. Cancer Biomarkers, 2009, 5(3):117-25.
15. Hisatomi T, Ishibashi T, Miller JW, Kroemer G. Pharmacological inhibition of mitochondrial membrane permeabilization for neuroprotection. Exp Neurol. 2009 Aug;218(2):347-52.
16. Hou JM, Greystoke A, Lancashire L, Cummings J, Ward T, Board R, Amir E, Hughes S, Krebs M, Hughes A, Ranson M, Lorigan P, Dive C, Blackhall FH. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol. 2009; 175(2):808-16.
17. Jaspers J.E., S. Rottenberg, J. Jonkers. Therapeutic options for triple-negative breast cancers with defective homologous recombination. Biochim Biophys Acta 2009, 1796, 266-280.
18. Kepp O, Galluzzi L, Giordanetto F, Tesniere A, Vitale I, Martins I, Schlemmer F, Adjemian S, Zitvogel L, and Kroemer G. Disruption of the PP1/GADD34 complex induces calreticulin exposure. Cell Cycle. 2009 Dec;8(23):3971-7
19. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri E, Baehrecke E, Blagosklonny MV, El-Deiry WS, Golstein P, Green DR, Hengartner M, Knight RA, Kumar S, Lipton S, Malorni W, Nunez G, Peter ME, Tschopp J, Yuan J, Zhivotovsky B, Melino G. Classification of cell death: Recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009 Jan;16(1):3-11.
20. Lengqvist J, Andrade J, Yang Y, Alvelius G, Lewensohn R, Lehtiö J. Robustness and accuracy of high speed LC-MS separations for global peptide quantitation and biomarker discovery. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 May 1;877(13):1306-16. Epub 2009 Feb 28.
21. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009 Mar;9(3):153-66.
22. Martins I, Tesniere A, Kepp O, Michaud M, Schlemmer F, Senovilla L, Séror C, Métivier D, Perfettini JL, Zitvogel L, Kroemer G. Chemotherapy induces ATP release from tumor cells. Cell Cycle. 2009. 8(22): 3723 – 3728.
23. Olaussen KA, Commo F, Tailler M, Lacroix L, Vitale I, Raza SQ, Richon C, Dessen P, Lazar V, Soria JC, Kroemer G. Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines. Oncogene. (2009)  28(48):4249-60.
24. Olsson M, Vakifahmetoglu H, Abruzzo PM, Högstrand K, Grandien A, Zhivotovsky B. DISC-mediated activation of caspase-2 in DNA damage-induced apoptosis. Oncogene. 2009 May 7;28(18):1949-59. Epub 2009 Apr 6.
25. Ott M, Norberg E, Zhivotovsky B, Orrenius S. Mitochondrial targeting of tBid/Bax: a role for the TOM complex? Cell Death Differ. 2009 Aug;16(8):1075-82.
26. Pajic M., J.K. Iyer, A. Kersbergen, E. van der Burg, A.O. Nygren, J. Jonkers, P. Borst, S. Rottenberg. Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer. Cancer Research 2009, 69, 6396-63404.
27. Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC, Durchschlag M, Joza N, Pierron G, van Endert P, Yuan J, Zitvogel L, Madeo F, Williams DB, Kroemer G. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J. 2009 Mar 4;28(5):578-90.
28. Pernemalm M, De Petris L, Eriksson H, Brandén E, Koyi H, Kanter L, Lewensohn R, Lehtiö J. Use of narrow-range peptide IEF to improve detection of lung adenocarcinoma markers in plasma and pleural effusion. Proteomics. 2009 Jul;9(13):3414-24.
29. Pernemalm M, Lewensohn R, Lehtiö J. Affinity prefractionation for MS-based plasma proteomics. Proteomics. 2009 Mar;9(6):1420-7. Review.
30. Rottenberg S., M. Pajic, J. Jonkers. Studying drug resistance using genetically engineered mouse models for breast cancer. Methods Mol Biol 2009, 596, 33-45.
31. Ståhl S., Fung E., Adams C., Lengqvist J., Mörk B., Stenerlöw B., Lewensohn R, Lehtiö J, Zubarev R., Viktorsson K. Proteomics and Pathway Analysis Identifies JNK-signaling as Critical for High-LET Radiation-induced Apoptosis in Non-Small Lung Cancer Cells. Mol Cel. Prot. 2009, 8(5):1117-29. Epub 2009 Jan 23.
32. Tan C.S., Salim A., Ploner A., Lehtiö J., Chia K.S., Pawitan Y. Correlating gene and protein expression data using maximum covariance analysis. BMC Bioinformatics. 2009 Sep 1;10(1):272.
33. Tao Y, Leteur C, Calderaro J, Girdler F, Zhang P, Frascogna V, Varna M, Opolon P, Castedo M, Bourhis J, Kroemer G, Deutsch E. The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe. Cell Cycle. 2009 Oct 1;8(19):3172-81.
34. Tubbs JL, Latypov V, Kanugula S, Butt A, Melikishvili M, Kraehenbuehl R, Fleck O, Marriott, A, Watson AJ, Verbeek, B, McGown G, Thorncroft M, Santibanez-Koref MF, Millington C, Arvai AS, Kroeger MD, Peterson LA, Williams DM, Fried MG, Margison GP, Pegg AE and Tainer JA. Alkylated DNA damage flipping bridges base and nucleotide excision repair. Nature 459(7248):808-813 (2009)
35. Urosevic J, Sum EY, Moneo V, Drosten M, Dhawahir A, Becerra M, Carnero A, Barbacid M. Using cells devoid of RAS proteins as tools for drug discovery. Mol Carcinog. 2009 Nov;48(11):1038-47.
36. Vallacchi V, Rodolfo M. Regulatory role of CCN3 in melanoma cell interaction with the extracellular matrix. Cell Adh Migr. 2009; 3(1): 7-10.
37. van Leeuwen F.W., T. Buckle, A. Kersbergen, S. Rottenberg, K.G. Gilhuijs. Non-invasive functional imaging of P-glycoprotein-mediated doxorubicin resistance in a mouse model for hereditary breast cancer to predict response, and assign P-gp inhibitor sensitivity. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 406-12.
38. Watson AJ, Middleton MR, McGown G, Thorncroft M, Ranson M, Hersey P, McArthur G, Davis ID, Thomson D, Beith J, Haydon A, Kefford R, Lorigan P, Mortimer P, Sabharwal A, Hayward O, Margison GP. O6-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. Br J Cancer. 2009 Apr 21;100(8):1250-1256.
39. Zhivotovsky B, Galluzzi L, Kepp O, Kroemer G. Adenine nucleotide translocase: a component of the phylogenetically conserved cell death machinery. Cell Death Differ. 2009 Nov;16(11):1419-25.
40. Zhivotovsky B, Orrenius S. Clinical perspectives of cell death: where we are and where to go. Apoptosis. 2009 Apr;14(4):333-5.

2008

1. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, André F, Delaloge S, Tursz T, Kroemer G*, Zitvogel L*. (Shared senior authorship). Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007 Sep;13(9):1050-9.
2. Borst, Rottenberg and Jonkers. How do real tumors become resistant to cisplatin? Cell Cycle (2008) 7, 1353-1359.
3. Crosbie PA, McGown G, Thorncroft MR, O'Donnell PN, Barber PV, Lewis SJ, Harrison KL, Agius RM, Santibáñez-Koref MF, Margison GP, Povey AC. Association between lung cancer risk and single nucleotide polymorphisms in the first intron and codon 178 of the DNA repair gene, O6-alkylguanine-DNA alkyltransferase. Int J Cancer. 2008. 122(4):791-5.
4. Deniaud A, Sharaf el dein O, Maillier E, Poncet D, Kroemer G, Lemaire C, Brenner C. Endoplasmic reticulum stress induces calcium-dependent permeability transition, mitochondrial outer membrane permeabilization and apoptosis. Oncogene. 2008 Jan 10;27(3):285-99.
5. Eriksson H., Lengqvist J., Hedlund J., Uhlén K., Orre LM., Bjellqvist B., Persson B., Lehtiö J., Jakobsson PJ.  Quantitative membrane proteomics applying narrow range peptide isoelectric focusing for studies of lung cancer resistance mechanisms. Proteomics. 2008 Aug;8(15):3008-18.
6. Gallego MA, Ballot C, Kluza J, Hajji N, Martoriati A, Castéra L, Cuevas C, Formstecher P, Joseph B, Kroemer G, Bailly C, Marchetti P. Overcoming chemoresistance of non-small cell lung carcinoma through restoration of an AIF-dependent apoptotic pathway. Oncogene. 2008 Mar 27;27(14):1981-92
7. Giulia Bertolini, Laura Paleari, Alessia Catassi, Luca Roz, Alfredo Cesario, Gabriella Sozzi and Patrizia Russo. In vivo cancer imaging with semiconductor quantum dots. Current Pharmaceutical Analysis 4 (4), 197-205, 2008 (IF 1.16)
8. Gogvadze, V., Orrenius, S., and Zhivotovsky, B. Mitochondria in cancer cells: what is so special about them? Trends Cell. Biol., 2008: 18, 165-173.
9. Hoffmann J, Vitale I, Buchmann B, Galluzzi L, Schwede W, Senovilla L, Skuballa W, Vivet S, Lichtner RB, Vicencio JM, Panaretakis T, Siemeister G, Lage H, Nanty L, Hammer S, Mittelstaedt K, Winsel S, Eschenbrenner J, Castedo M, Demarche C, Klar U, Kroemer G. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone.  Cancer Res. 2008 Jul 1;68(13):5301-8.
10. Kannegiesser C, Spatz A, Michiels S, Eychene A, Dessen P, Lazar V, Winnepenninckx V, Lesueur F, Druillennec S, Robert C, van den Oord J, Sarasin A, Bressac-de Paillerets B. Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas. Mol Oncol. 2008 Apr;1(4):425-30.
11. Kroemer G, Levine B. Autophagic cell death. The story of a misnomer. Nat Rev Mol Cell Biol. 2008 Dec;9(12):1004-1010
12. Lehtiö J. and Lewensohn R. Discovery of novel biomarkers using genomics and proteomics – technical tools. An introduction to cancer biomarkers in NSCLC – mehtods and platforms, clinical data and future aspects. Edited by Fred R. Hirsch.1^st edition, Aug 2008.  Book chapter.
13. Maiuri MC, Criollo A, Tasdemir E, Vicencio JM, Tajeddine N, Hickman JA, Geneste O, Kroemer G. BH3-only proteins and BH3 mimetics induce autophagy by competitively disrupting the interaction between Beclin 1 and Bcl-2/Bcl-X(L). Autophagy. 2007 Jul-Aug;3(4):374-6.
14. Maiuri MC, Le Toumelin G, Criollo A, Rain JC, Gautier F, Juin P, Tasdemir E, Pierron G, Troulinaki K, Tavernarakis N, Hickman JA, Geneste O, Kroemer G. Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO J. 2007 May 16;26(10):2527-39.
15. Morselli E, Maiuri MC, Tasdemir E, Galluzzi L, Kepp O, Criollo A, Vicencio JM, Soussi T, Kroemer G. Mutant p53 protein localized in the cytoplasm inhibits autophagy. Cell Cycle. 2008 Oct;7(19):3056-61.
16. Norberg, E., Gogvadze, V., Ott, M., Horn, M., Uhlén, P., Orrenius, S., and Zhivotovsky, B.  An increase in intracellular Ca²⁺ is required for the activation of mitochondrial calpain to release AIF during cell death. Cell Death Differ. 2008: 15, 1857-1864.
17. Panaretakis T, Joza N, Modjtahedi N, Tesniere A, Vitale I, Durchschlag M, Fimia GM, Kepp O, Piacentini M, Froehlich KU, van Endert P, Zitvogel L, Madeo F, Kroemer G. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ. 2008 Sep;15(9):1499-509.
18. Pernemalm M., Orre L., Lengqvist J., Wikström P., Lewensohn R., Lehtiö J. Evaluation of three principally different intact protein pre-fractionation methods for plasma biomarker discovery. J Proteome Res. 2008 Jul;7(7):2712-22.
19. Rottenberg and Jonkers. Modeling therapy resistance in genetically engineered mouse cancer models. Drug Resist Updat (2008)11,51-60.
20. Rottenberg et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U SA (2008)105, 17079-17084.
21. Sayan, A.E., Sayan, B.S., Gogvadze, V., Dinsdale, D., Nyman, U., Hansen, T.M., Zhivotovsky, B., Cohen, G.M., Knight, R.A., and Melino, G. p73 and caspase-cleaved p73 fragments localize to mitochondria and augment TRAIL-induced apoptosis. Oncogene, 2008: 27, 4363-4372.
22. Shen, J., Vakifahmetoglu, H., Stridh, H., Zhivotovsky, B., and Wiman, K.G. PRIMA-1^MET induces mitochondrial apoptosis through activation of caspase-2. Oncogene, 2008: 27, 6571-6580.
23. Tajeddine N, Galluzzi L, Kepp O, Hangen E, Senovilla L, Morselli E, Zamzami N, Araujo N, Modjtahedi  N, Harel-Belan A, Kroemer G. Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death. Oncogene 2008, 27: 4221-32.
24. Tamm, C., Zhivotovsky, B., and Ceccatelli, S. Caspase-2 activation in neural stem cells undergoing oxidative stress-induced apoptosis. Apoptosis, 2008: 13, 354-363.
25. Tasdemir E, Kepp O, Morselli E, Vitale I, Galluzzi L, Maiuri C, Kroemer G. p53 represses autophagy in a cell cycle-dependent fashion. Cell Cycle. 2008 Oct;7(19):3006-11.
26. Tasdemir E, Maiuri MC, Galluzzi L, Vitale I, Djavaheri-Mergny M, D'Amelio M, Criollo A, Morselli E, Zhu C, Harper F, Nannmark U, Samara C, Pinton P, Vicencio JM, Carnuccio R, Moll UM, Madeo F, Paterlini-Brechot P, Rizzuto R, Szabadkai G, Pierron G, Blomgren K, Tavernarakis N, Codogno P, Cecconi F, Kroemer G. Regulation of autophagy by cytoplasmic p53. Nat Cell Biol. 2008 Jun;10(6):676-87.
27. Tufi R, Panaretakis T, Bianchi K, Criollo A, Fazi B, Di Sano F, Tesniere A, Kepp O, Paterlini-Brechot P, Zitvogel L, Piacentini M, Szabadkai G, Kroemer G. Reduction of endoplasmic reticulum Ca2+ levels favors plasma membrane surface exposure of calreticulin. Cell Death Differ. 2008 Feb;15(2):274-82.
28. Vaculova, A., and Zhivotovsky, B. Caspases: determination of their activities in apoptotic cells. Meth. Enzymol. 2008, 442, 157-181.
29. Vakifahmetoglu H, Olsson M, Tamm C, Heidari N, Orrenius S, Zhivotovsky B. DNA damage induces two distinct modes of cell death in ovarian carcinomas. Cell Death Differ. 2008 Mar; 15(3):555-66.
30. Vakifahmetoglu, H., Olsson, M., and Zhivotovsky, B. Death through a tragedy: Mitotic Catastrophe. Cell Death Differ. 2008: 15, 1153-1162.
31. Vallacchi V, Daniotti M, Ratti F, Di Stasi D, Deho P, De Filippo A,Tragni G, Balsari A, Carbone A, Rivoltini L, Parmiani G, Lazar N, Perbal B, Rodolfo M. CCN3/nephroblastoma overexpressed matricellular protein regulates integrin expression, adhesion, and dissemination in melanoma. Cancer Res 2008. 68(3):715-23
32. Verbeek B, Southgate T, Gilham D, Margison GP. O⁶-methylguanine-DNA methyltransferase inactivation and chemotherapy. Br Med Bull. 2008;85:17-33.
33. Vitale I, Senovilla L, Galluzzi L, Criollo A, Vivet S, Castedo M, Kroemer G. Chk1 inhibition activates p53 through p38 MAPK in tetraploid cancer cells. Cell Cycle. 2008 Jul;7(13):1956-61.

2007

1. Borst P, Jonkers J, Rottenberg S. What makes tumors multidrug resistant? Cell Cycle. 2007 Aug; 6(22):2782-7.

2. de La Motte Rouge T, Galluzzi L, Olaussen KA, Zermati Y, Tasdemir E, Robert T, Ripoche H, Lazar V, Dessen P, Harper F, Pierron G, Pinna G, Araujo N, Harel-Belan A, Armand JP, Wong TW, Soria JC, Kroemer G. A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res. 2007 Jul 1; 67(13):6253-62.

3. De Milito A, Iessi E, Logozzi MA, Lozupone F, Spada M, Marino ML, Federici C, Perdicchio M, Matarrese P, Lugini L, Nilsson A, Fais S. Proton pump inhibitors induce apoptosis of human B cell tumors through a caspase-independent mechanism involving reactive oxygen species. Cancer Res. 2007 Jun 1; 67(11):5408-17.
4. Fais S, De Milito A, You H, Qin W. Targeting vacuolar H⁺-ATPases as a new strategy against cancer. Cancer Res. 2007 Nov 15; 67(22):10627-30.
5. Gogvadze V, Zhivotovsky B. Alteration of mitochondrial function and cell sensitization to death. J Bioenerg Biomembr. 2007 Feb; 39(1):23-30.
6. Hornillo-Araujo AR, Burrell AJ, Aiertza MK, Shibata T, Hammond DM, Edmont D, Adams H, Margison GP, Williams DM. The synthesis and properties of tricyclic analogues of S(6)-methylthioguanine and O(6)-methylguanine. Nucleosides Nucleotides Nucleic Acids. 2007; 26(8-9):1099-102.
7. Kauffmann A, Rosselli F, Lazar V, Winnepenninckx V, Mansuet-Lupo A, Dessen P, van den Oord JJ, Spatz A, Sarasin A. High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene. 2008 Jan 24;27(5):565-73.
8. Kropotov A, Usmanova N, Serikov V, Zhivotovsky B, Tomilin N. Mitochondrial targeting of human peroxiredoxin V protein and regulation of PRDX5 gene expression by nuclear transcriptional factors controlling biogenesis of mitochondria. FEBS J. 2007 Nov; 274(22):5804-14.
9. Lees NP, Harrison KL, Hall CN, Margison GP, Povey AC. Human colorectal mucosal O6-alkylguanine DNA-alkyltransferase activity and DNA-N7-methylguanine levels in colorectal adenoma cases and matched referents. Gut 2007 Mar; 56(3):380-4.
10. Lengqvist J, Uhlén K, Lehtiö J. iTRAQ compatibility of peptide immobilized pH gradient isoelectric focusing. Proteomics. 2007 Jun; 7(11):1746-52.
11. Margison GP, Butt A, Pearson SJ, Wharton S, Watson AJ, Marriott A, Caetano CM, Hollins JJ, Rukazenkova N, Begum G, Santibáñez-Koref MF. Alkyltransferase-like proteins. DNA Repair (Amst). 2007 Aug 1; 6(8):1222-8.
12. Mouhamad S, Galluzzi L, Zermati Y, Castedo M, Kroemer G. Apaf-1 Deficiency Causes Chromosomal Instability. Cell Cycle. 2007 Dec; 6(24):3103-3107.
13. Orre LM, Pernemalm M, Lengqvist J, Lewensohn R, Lehtiö J. Up-regulation, modification, and translocation of S100A6 induced by exposure to ionizing radiation revealed by proteomics profiling. Mol Cell Proteomics. 2007 Dec; 6(12):2122-31.
14. Ott M, Gogvadze V, Orrenius S, Zhivotovsky B. Mitochondria, oxidative stress and cell death. Apoptosis. 2007 May;12(5):913-22.
15. Ott M, Norberg E, Walter KM, Schreiner P, Kemper C, Rapaport D, Zhivotovsky B, Orrenius S. The mitochondrial TOM complex is required for tBid/Bax-induced cytochrome c release. J Biol Chem. 2007 Sep 21; 282(38):27633-9.
16. Ott M, Zhivotovsky B, Orrenius S. Role of cardiolipin in cytochrome c release from mitochondria. Cell Death Differ. 2007 Jul; 14(7):1243-7.
17. Povey AC, Margison GP, Santibáñez-Koref MF. Lung cancer risk and variation in MGMT activity and sequence. DNA Repair (Amst) 2007 Aug 1; 6(8):1134-44.
18. Ranson M, Hersey P, Thompson D, Beith J, McArthur GA, Haydon A, Davis ID, Kefford RF, Mortimer P, Harris PA, Baka S, Seebaran A, Sabharwal A, Watson AJ, Margison GP, Middleton MR. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol 2007 Jun 20; 25(18):2540-5.
19. Rottenberg S, Jonkers J. Modeling therapy resistance in genetically engineered mouse cancer models. Drug Resist Updat. 2008 Feb-Apr;11(1-2):51-60. Epub 2007 Dec 31.
20. Rottenberg S, Nygren AO, Pajic M, van Leeuwen FW, van der Heijden I, van de Wetering K, Liu X, de Visser KE, Gilhuijs KG, van Tellingen O, Schouten JP, Jonkers J, Borst P. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci U S A. 2007 Jul 17; 104(29):12117-22.
21. Vitale I, Galluzzi L, Vivet S, Nanty L, Dessen P, Senovilla L, Olaussen KA, Lazar V, Prudhomme M, Golsteyn RM, Castedo M, Kroemer G. Inhibition of Chk1 Kills Tetraploid Tumor Cells through a p53-Dependent Pathway. PLoS ONE. 2007 Dec 26; 2(12):e1337
22. Zermati Y, Mouhamad S, Stergiou L, Besse B, Galluzzi L, Boehrer S, Pauleau AL, Rosselli F, D'Amelio M, Amendola R, Castedo M, Hengartner M, Soria JC, Cecconi F, Kroemer G. Nonapoptotic role for Apaf-1 in the DNA damage checkpoint. Mol Cell. 2007 Nov 30; 28(4):624-37.
23. Zhang H, Mizumachi T, Carcel-Trullols J, Li L, Naito A, Spencer HJ, Spring PM, Smoller BR, Watson AJ, Margison GP, Higuchi M, Fan CY. Targeting human 8-oxoguanine DNA glycosylase (hOGG1) to mitochondria enhances cisplatin cytotoxicity in hepatoma cells. Carcinogenesis. 2007 Aug; 28(8):1629-37.